Arcturus Therapeutics (ARCT) Tops Q4 EPS by 63c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2023 Financial Update and Pipeline Progress
March 7, 2024 4:01 PM ESTKostaive® anticipated to launch in Japan this year
ARCT-032 remains on track for Phase 1b interim data in Q2
ARCT-810 remains on track for Phase 2 interim data by the end of Q2
ARCT-2138 (Quadrivalent LUNAR-FLU) Phase 1 study for seasonal influenza vaccine initiated
New STARR® vaccine discovery programs initiated for Lyme Disease and Gonorrhea
Cash runway extended to Q1 2027
Investor conference call at 4:30 p.m. ET today
SAN DIEGO--(BUSINESS WIRE)-- Arcturus... More
